Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Nxera Pharma Proposes Changes to its Board of Directors
Mr. Takeo Morooka nominated for appointment as new External Director Ms. Miwa Seki and Mr. Noriaki Nagai to retire from the Board of Directors Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera”…
RaQualia Pharma FY Net Y273.00M Vs Loss Y495.00M
RaQualia Pharma Inc. (4579.TO) Japan Year Ended December 31 GROUP 2025 2024 Revenue Y3.98 bln Y3.11 bln Operating Profit Y483.00 mln (Y213.00 mln) Pretax Profit Y437.00 mln (Y361.00 mln) Net Profit Y273.00 mln (Y495.00 mln) Per share Earnings…
Solasia Pharma FY Loss Y876.00M Vs Loss Y1.94B
Solasia Pharma KK (4597.TO) Japan Year Ended December 31 GROUP 2025 2024 Revenue Y429.00 mln Y316.00 mln Operating Profit (Y861.00 mln) (Y1.95 bln) Pretax Profit (Y876.00 mln) (Y1.96 bln) Net Profit (Y876.00 mln) (Y1.94 bln) Per share Earnings…
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth…
Prices, pipelines and patent cliffs: Inside pharma's big reset
Pharma earnings weren't the main focus for drugmakers this quarter. '2025 was about understanding kind of the rules of the future of the game,' McKinsey Senior Partner Greg Graves told CNBC. In addition to political dealings, companies are facing a…
New launches to keep growth momentum healthy for Sun Pharma stock
Incremental gains for the company, and the listed pharma universe more broadly, also stemmed from positive sentiment around the India–US trade deal. About a third of Sun Pharma's revenues come from the US market. The India–US trade…
The top performing pharma and biotech stocks as group sees resurgence (PJP:NYSEARCA)
Pharmaceutical (PJP), (XPH), (PPH) and biotechnology stocks (XBI), (BBH) have officially returned to favor on Wall Street, according to Michael Yee, global head of biotechnology equity research at UBS. In an interview with CNBC, Yee highlighted a…
Swiss pharma's global success meets worries at home
Last year was a good year for Swiss pharma. Roche's sales rose 7% (at constant exchange rates) to CHF61.5 billion ($79.8 billion), driven by strong demand for drugs for multiple sclerosis, eye diseases and Haemophilia A. With ten new molecules…
Ascentage Pharma Group International (AAPG) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Ascentage Pharma Group International (AAPG) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 February 12, 2026 9:30 AM EST Veet Misra - Chief Financial Officer Bradley Canino - Guggenheim Securities, LLC Here at the Guggenheim…
Torrent Pharma Q3FY26 results: Profit rises 26%; revenue up 17.6%
Ahmedabad-based Torrent Pharmaceuticals on Friday posted a 26 per cent year-on-year (Y-o-Y) increase in its net profit on a consolidated basis for the third quarter of the financial year (Q3FY26) at Rs 635 crore. Revenue from operations also grew…
Mankind Pharma consolidated net profit rises 7.50% in the December 2025 quarter
Last Updated: Feb 13 2026 | 2:32 PM IST Sales rise 11.52% to Rs 3567.20 crore Net profit of Mankind Pharma rose 7.50% to Rs 408.75 crore in the quarter ended December 2025 as against Rs 380.23 crore during the previous quarter ended December 2024.
Torrent Pharma Q3 result: Net profit up 26% to ₹635 cr, dividend declared
Torrent Pharmaceuticals on Friday reported a 26.2 per cent jump in its consolidated net profit to ₹635 crore in the third quarter of the financial year 2025-26 (Q3FY26). During the same quarter last year, the company recorded a profit of…
Europe's machinery and pharma strengths give leverage over US and China, report finds
Europe's hold over machines, pharmaceuticals and other products in global supply-chains give leverage over the United States and China, according to a report published Friday (13 February), ahead of the Munich Security Conference. The study…
BridgeBio Pharma (NASDAQ:BBIO) Given New $83.00 Price Target at Oppenheimer
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) had its target price raised by equities research analysts at Oppenheimer from $81.00 to $83.00 in a report issued on Friday, Benzinga reports. The firm presently has an 'outperform' rating on the…
Ex-Pharma Exec Fights AGs' Quick Win Bid In Antitrust Case
A former pharmaceutical marketing executive urged a Connecticut federal court to reject summary judgment sought against him by state attorneys general pursuing wider price-fixing litigation against most of the generic drug... To view the full…
Receive a Daily briefing on Pharma Industry News
Get Started